Generic Semaglutide: Where It Is Available and When

1. Why did semaglutide go generic in 2026?

A drug patent normally lasts 20 years from the date it is filed. Semaglutide’s international patent application was filed on March 20, 2006, so national patents in countries using the standard 20-year term expired on March 20, 2026. That includes India, China and Brazil (Abel + Imray, April 2026).

Rich markets are different because they let drugmakers extend patent life to make up for years lost in clinical trials and regulatory review. Europe does this with supplementary protection certificates (SPCs), Japan and the US with patent term extensions. Those extensions are why the same molecule is generic in India but protected in Germany or Ohio (Abel + Imray).

Novo Nordisk saw this coming. Its 2025 annual filing to the US Securities and Exchange Commission said it “anticipates that the expiration of certain patents could impact sales starting in 2026” (Novo Nordisk Form 20-F 2025), and in February 2026 it warned that sales could fall 5% to 13% that year, citing patent expirations in India, Canada, Brazil and China (CNBC).

A 2026 analysis in Obesity found that the 12 countries with 2026 expiry account for 47% of global obesity and 49% of global type 2 diabetes, and that no semaglutide patent filings were identified in another 150 countries. By its estimate, generic injectable semaglutide could be available by the end of 2026 in 162 countries covering 84% of clinical obesity worldwide (Obesity, 2026).

2. What happened in India?

India was the first large market to open, and it moved fast. The patent expired on Friday, March 20, 2026, and generics launched over that weekend (CNBC). Six months later, a regional industry analysis counted 12 generic makers selling 20 brands (BioPharma APAC, October 2026).

Source: BioPharma APAC. Before expiry, Novo Nordisk’s Indian retail price ran from Rs 8,800 to 10,000 depending on dose, after a 37% Wegovy price cut (CNBC). Novo then cut again from April 1, 2026, to Rs 1,415 per weekly starting dose of Ozempic and Wegovy, and launched second brands with partners: Poviztra (Wegovy, with Emcure) and Extensior (Ozempic, with Abbott India). By April, generics held about half of semaglutide sales by value and about four in five units (BioPharma APAC; CNBC).

India also has generic oral semaglutide: Dr. Reddy’s sells tablets, the generic counterpart of Rybelsus. Some Indian generics come in multi-dose vials rather than pens, which is cheaper but means each dose is drawn up with a syringe. A 2026 commentary in The Lancet Regional Health: Southeast Asia framed India’s generic GLP-1 drugs as an opportunity to close the cardiovascular evidence gap in Indian patients (Lancet Regional Health Southeast Asia, 2026).

3. What happened in Canada?

Canada’s story is unusual. Novo Nordisk’s Canadian semaglutide patent, CA 2601784, lapsed after the company did not pay a 2019 maintenance fee, and Canadian rules do not allow a lapsed patent to be revived. Novo has said this was a deliberate strategic choice; patent commentators have debated whether it was. What kept generics out until 2026 was Canada’s data protection period for the brand’s clinical data, not the patent (Reddie & Grose, October 2025; Abel + Imray).

Health Canada’s approvals so far:

Sources: Health Canada, April 28; Health Canada, May 1; Health Canada, June 29; Pearce IP, September 18.

The April approval made Canada the first G7 country to authorize a generic semaglutide. Health Canada described the product as a “complex synthetic product” that is pharmaceutically equivalent to the brand, and said it completed the review within its 180-day target. In June it said six more generic submissions were under review and that it would “continue to monitor the safety and effectiveness of all generic semaglutide products” (Health Canada, April 28; Health Canada, June 29).

Dr. Reddy’s and Apotex both launched their Ozempic generics on May 14, 2026 (Pearce IP). One industry analysis reported Dr. Reddy’s list price at about half of Novo’s and said its Canadian supply was paused in July, with resumption expected by November (BioPharma APAC). Health Canada notes that many generics in Canada cost 45% to 90% less than brands, but has not published a semaglutide price (Health Canada, May 1).

4. What about China, Brazil and other countries?

China

China’s compound patent also expired on March 20, 2026, after China’s Supreme People’s Court upheld its validity in December 2025 (Novo Nordisk Form 20-F). Even so, no domestic semaglutide had been approved by late September 2026, despite applications from 10 to 12 companies (BioPharma APAC).

The obstacle is data protection. Ozempic’s Chinese marketing authorization is held by a Swiss Novo Nordisk subsidiary, and under the China-Switzerland Free Trade Agreement, undisclosed trial data must be protected for at least six years from approval. Ozempic was approved in China in April 2021, so that protection runs to April 2027. Jiuyuan Gene, the first filer, reported its review as suspended, and Livzon said it expected approval in the second quarter of 2027 (Tiger Brokers news, April 2026). New Chinese rules that took effect on May 15, 2026 also set six years of data protection for originator drugs (BioPharma APAC).

Brazil

Brazil’s patent expired in March 2026 (Abel + Imray). On July 29, 2026, Sandoz announced that Brazil’s regulator, ANVISA, had approved Owozy, a generic Ozempic developed by Adalvo, for type 2 diabetes, with launch expected in the second half of 2026 (Pearce IP, July 2026). Sun Pharma has also received approval and will sell through Hypera; Dr. Reddy’s Brazilian launch has been delayed (BioPharma APAC). Local maker EMS has also had a semaglutide pen approved, but reports differ on whether it was registered as a generic or as a new medicine, so it is left out of the table above.

Elsewhere

Sun Pharma received approval in South Africa in July 2026. Biocon has filed in Saudi Arabia and Turkey, Hetero reports sales in Africa, Asia and the Middle East, and Jiuyuan has licensed its product to Fosun for the Middle East, Africa and parts of Southeast Asia (BioPharma APAC). Dr. Reddy’s has said it plans to export to Canada, Turkey and Brazil (Abel + Imray). Status changes month by month, so local regulators are the authority for any specific country.

5. When will generic semaglutide come to the US and Europe?

United States

The FDA’s Orange Book, the official list of patents attached to approved drugs, lists US patent 8,129,343 as a drug-substance patent on Ozempic and Wegovy expiring on December 5, 2031 (Orange Book, Ozempic; Orange Book, Wegovy). Novo Nordisk’s own 2025 filing says: “Compound patent expiry in the US for the semaglutide branded products - Ozempic, Rybelsus, and Wegovy - is 2032” (Form 20-F).

Several other things shape the real date:

• Settlements. Generic makers filed abbreviated applications (ANDAs) challenging Novo’s patents. Novo settled the Ozempic litigation with Alvogen, Rio Biopharmaceuticals, Sun, Dr. Reddy’s, Mylan, Zydus and Apotex. “All terms of the agreements are confidential,” so the agreed entry dates are not public (Form 20-F).
• A tentative approval. On April 10, 2026, Apotex announced the first FDA tentative approval for a generic Ozempic, developed with Orbicular. Tentative approval means the FDA found the product meets its standards but it cannot be sold until patents and exclusivities allow (Apotex).
• Later patents. The Orange Book lists further patents on Wegovy, mostly device and use patents, running to 2038, 2040 and February 2041 (Orange Book, Wegovy). The nonprofit I-MAK has counted at least 49 semaglutide patents, and critics argue these could delay some generics until 2042 (NBC News, May 2026).

Experts quoted by NBC News put US generics “at least” at the end of 2031, with one saying it could take “much, much longer” (NBC News). There is a useful precedent: after similar settlements, generic liraglutide, the active ingredient in Victoza, reached the US in June 2024 (Form 20-F).

Europe and Japan

The European basic patent expired in March 2026, but SPCs extend protection to about March 2031 in member states where they are in force. Japan’s protection is expected to run to about 2031 (Abel + Imray). As in the US, secondary patents on formulations, doses and pens may push some products later.

6. How is a generic different from compounded semaglutide?

These two are often blurred together online, and the difference matters.

Sources: Health Canada; FDA.

The FDA says that as of May 31, 2026 it had received 990 reports of adverse events associated with compounded semaglutide, and warns that some compounders sell semaglutide “salt forms,” which are “different active ingredients than are used in the approved drugs.” It also warns about counterfeit Ozempic and urges people to “only purchase from state-licensed pharmacies” (FDA). The full history of the shortage, the 503A and 503B pharmacy rules and the 2025 deadlines is in what is compounded semaglutide, and the product-level comparison is in Wegovy vs compounded semaglutide.

NBC News made the same point: compounded versions “are not considered true generics because the FDA has not reviewed or approved them for safety or effectiveness” (NBC News). In short, a generic is the brand’s equivalent with a regulator’s sign-off; a compounded product is a pharmacy preparation without one.

7. What does this mean for people in the United States?

No generic is legally on sale in the US. The first tentative approval exists, but Apotex cannot sell until patents and settlement terms allow (Apotex). Anything marketed to Americans as “generic Ozempic” today is either a foreign product, a compounded product, or something else.

Importing is generally not legal. The FDA states that “it is illegal for individuals to import drugs or devices into the U.S. for personal use,” and that a drug approved in another country but not in the US cannot be legally imported. It sometimes uses enforcement discretion for a personal supply of no more than three months, but only under conditions that include a serious condition for which effective treatment “may not be available domestically,” a product not marketed to US residents, and a US-licensed treating doctor (FDA personal importation). Semaglutide is available in the US, and the Canadian and Indian generics are not FDA-approved products.

Brand prices are moving anyway. Generic competition abroad and US policy pressure have pushed Novo Nordisk’s US prices down. NBC reported a $349 monthly cash price and plans to cut Ozempic and Wegovy list prices to $675 a month (NBC News). Novo’s 2025 filing also describes an agreement with the US administration expanding access to semaglutide through Medicare Part D, Medicaid and direct-to-patient cash channels in 2026 (Form 20-F).

Production costs are low. The Obesity analysis estimated generic injectable semaglutide could be made and sold at a profit for $28 to $140 per person per year, with injection devices a disproportionate share of the cost (Obesity, 2026). That gap between cost and US price is the backdrop to every debate about compounding, importation and patents.

Watch the 2031 to 2032 window. If settlements follow the liraglutide pattern, the first US generics could arrive around the compound patent’s end. The dates that matter are the Orange Book expiry, any disclosed settlement entry dates, and the FDA’s final approvals of pending ANDAs.

8. Does a generic work the same as the brand?

A regulator’s approval of a generic means it found the product equivalent to the brand in the ways that matter for that agency’s rules. Health Canada said its review ensures that differences between the products do not affect safety, efficacy or quality, and committed to ongoing monitoring (Health Canada, April 28). Semaglutide itself works the same way whoever makes it, through the GLP-1 receptor; the semaglutide guide covers its trials, doses and side effects.

What can differ is the device, the dose steps available, and the paperwork. Some generics come only in certain strengths or as vials. Indications can differ too: most of the first Canadian generics were approved only for type 2 diabetes, with Sevmia the first approved for weight management (Health Canada, June 29).

For anyone tracking injections, a switch between brands or makers is worth logging with the product name, strength and lot number, so that any change in side effects can be matched to a date. How GLP-1 tracking works covers what to record.

9. Generic Semaglutide FAQ

• Is there a generic semaglutide?

  Yes, outside the United States. Generic semaglutide injections are approved and sold in India (from March 2026) and Canada (from May 2026), and Brazil's regulator has approved several. In the US no generic is on the market; the first FDA tentative approval, for Apotex's generic Ozempic in April 2026, does not allow sales until patents and exclusivities expire.

• When will generic Ozempic be available in the US?

  Not before the end of 2031 under the current patent listings. The FDA Orange Book lists the main semaglutide patent as expiring December 5, 2031, and Novo Nordisk's 2025 annual filing states US compound patent expiry as 2032. Novo has settled with seven generic filers on confidential terms, so the exact entry date is not public.

• When does the semaglutide patent expire in Europe?

  The basic patent expired on March 20, 2026, but supplementary protection certificates extend protection to about March 2031 in European countries where they are in force. Japan's protection is also expected to run to about 2031.

• Is generic semaglutide the same as compounded semaglutide?

  No. A generic is approved by a regulator such as Health Canada or India's drug controller after being shown equivalent to the brand product in quality and performance. Compounded semaglutide is mixed by a pharmacy and, according to the FDA, is not FDA-approved and is not reviewed for safety, effectiveness or quality before it is sold.

• Is there a generic Wegovy?

  In Canada, yes. Health Canada approved Apotex's Sevmia on June 29, 2026 for chronic weight management in people aged 12 and over. In India, several generic makers sell semaglutide at weight-management strengths. There is no generic Wegovy in the US.

• Can Americans buy generic semaglutide from Canada or India?

  The FDA says it is generally illegal for individuals to import drugs for personal use, and a drug approved abroad but not in the US cannot legally be imported. The FDA sometimes uses enforcement discretion for a three-month personal supply in narrow circumstances, including when effective treatment is not available in the US, which is not the case for semaglutide. This page does not give legal or sourcing advice.

• How cheap is generic semaglutide?

  In India, monthly prices range from about Rs 1,290 for vial products to Rs 4,200 for Dr. Reddy's pens, against Novo Nordisk's earlier retail price of Rs 8,800 to 10,000. A 2026 study in Obesity estimated generic injectable semaglutide could be made for $28 to $140 per person per year, with the pen device a large share of the cost.

• Why did generics reach Canada before other rich countries?

  Novo Nordisk's Canadian semaglutide patent lapsed after a missed maintenance fee, and Canadian rules do not allow it to be revived. Once data protection ended, generics could be approved. Novo has said the lapse was a deliberate decision.

10. Sources